View all veterinary jobs
Methadyne can be administered for analgesia of moderate to severe pain in dogs and cats, to provide neuroleptanalgesia in combination with a neuroleptic drug and as part of a patient’s premedication protocol prior to general anaesthesia.
The new presentation will now be available alongside the 10ml vial to give greater flexibility and to help reduce drug wastage and streamline controlled drug stock management.
Jurox says Methadyne has proven compatibility when combined in the same syringe with other aqueous solutions for injection containing acepromazine as maleate and medetomidine and dexmedetomidine as hydrochlorides.
Methadyne has a shelf life of 24 months unbroached, and 28 days broached. After broaching, the bung can be punctured to draw up a dose of methadone as many times as required in 28 days.
Dan Cripwell MRCVS, senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution in our multidose methadone formulation, which is now available in both 5ml and 10ml vials.
"We constantly strive to provide the veterinary profession with first class clinical and technical support and, in this instance, we were able to assess what improvements could be made to our existing drug portfolio and respond to the profession’s feedback to help reduce wastage of controlled drugs when they are needed in smaller volume."
For further information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
Jurox says the reformulation will also help reduce waste associated with unpreserved ampule formulations and will help streamline portfolios with a requirement for only one buprenorphine listing.
Dr Dan Cripwell BSc (Hons) BVSc CertAVP (EM) CertAVP PgCert (VPS) MRCVS, Advanced Veterinary Practitioner and senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution of our multidose buprenorphine formulation. We constantly strive to provide the veterinary profession with first class clinical and technical support and our ability to perform in-house product research and development is also a great strength; this allows us to remain agile enough to make adaptations in an area where not much has changed in the past few years.
“In this instance, we were able to examine what improvements could be made to our existing drug portfolio and respond to the profession’s feedback with the redevelopment of the commonly utilised opioid analgesic, buprenorphine. Our hope is that, as well as the recent mixing claims added to the product licence, this development will encourage the best clinical use of the drug and, in turn, improve patient experience and outcome.”
For more information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
The course counts for four hours CPD, split into six short sessions which can be completed in your own time.
Presented by Dr Dan Cripwell BSc (Hons) BVSc CertAVP PgCert (VPS) MRCVS, Advanced Veterinary Practitioner and senior veterinary technical advisor at Jurox, the sessions consist of:
There is a quiz at the end of each module, following which, you can download a CPD certificate.
Suzy Ramsay, head of sales and marketing at Jurox (UK) Limited, said: “We are committed to developing unique and world class anaesthesia and analgesic products and practices within the animal health industry through the provision of up-to-date technical support and education. Our new Jurox Anaesthesia Academy CPD platform will enable veterinary professionals to adopt an evidence-based approach to their anaesthetic product choice and, in turn, help achieve the best possible anaesthetic outcomes for their patients.”
For access to the Jurox Anaesthesia Academy CPD platform, visit https://cpd.jurox.co.uk.
For further information, contact your local Jurox account manager, phone 0800 500 3171 or email customerservice@jurox.co.uk.
The recall is due to the fact that particulates have been found in identified batches of product during routine stability testing.
The affected batches are:
This issue only applies to the batches listed above. All other batches and the 20 ml pack size are not affected.
For further information regarding the recall, contact Richard Beckwith on 07584 099536 or: richard.beckwith@jurox.co.uk.
AceSedate for horses contains 10mg/ml acepromazine as its active ingredient, which the company says means a lower dose volume is required compared to the non-UK licensed equine acepromazine options available.
The dosage of AceSedate is 0.03-0.10 mg per kg bodyweight, however Jurox recommends that the lower end of the dose range is always selected where possible. It can be administered via intramuscular or slow intravenous injection.
AceSedate is supplied in a multidose vial and the shelf life after opening the immediate packaging is 28 days.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "The launch of AceSedate means injectable acepromazine is now licensed in the UK for horses, giving vets peace-of-mind that a licensed product is now available. It is a welcome addition to our equine anaesthesia, analgesia and sedation portfolio."
For more information, visit: www.jurox.com/uk, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail customerservice@jurox.co.uk.
The support pack features information on the role anaesthetic induction agents can play in the maintenance of anaesthesia to help veterinary surgeons provide appropriate care for their patients.
The pack includes a user guide to achieving the best outcome when using Alfaxan for the induction and maintenance of anaesthesia, a summary of peer-reviewed key clinical papers on the use of Alfaxan and how it can be used for the maintenance of anaesthesia, an article discussing the use of intravenous agents to maintain anaesthesia in the dog and cat, frequently asked questions and an Alfaxan dosage chart for CRI (Constant Rate Infusion) and intermittent bolus.
To download the pack, visit www.alfaxan.co.uk.
Richard Beckwith, country manager for Jurox (UK) Ltd. said: "We have received a significant increase in enquiries following the isoflurane supply issues.
"The new support pack will provide veterinary professionals with comprehensive information on Alfaxan to help practices develop options in providing appropriate anaesthesia for patients."
For more information, call Jurox customer services on 0800 500 3171, or e-mail: info@jurox.co.uk.
In case you need any reminding, acepromazine belongs to the phenothiazine family and acts as a dopamine receptor antagonist, providing calming effects1, 2. It causes sedation and anxiolysis, which is initially dose dependent, plateauing at higher doses1, 3. It is metabolised in the liver and has a long duration of action of approximately six hours in healthy patients1.
For best results AceSedate should be combined with an opioid (neuroleptanalgesia) to improve the quality and reliability of sedation and provide analgesia1, 2, 3.
Richard Beckwith, country manager of Jurox (UK) Ltd said: "AceSedate is a welcome addition to our analgesia and anaesthesia range providing our customers with a high-quality product at an economical price."
For further information, visit www.jurox.com/uk, contact your Jurox technical sales rep, ring the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
References
Jurox says Alfaxan Multidose is the bioequivalent to unpreserved Alfaxan, however the preserved formulation reduces the risk of microbial contamination, providing repeatable and reliable anaesthesia.
Alfaxan Multidose is available in two presentations of 10ml and 20ml, with the 20ml presentation priced at an equivalent price per ml as the current 10ml Alfaxan unpreserved presentation.
Jurox says there has been unprecedented interest in the new product, with the company taking pre-orders for the 20ml presentation from 60 different accounts at BSAVA this year.
Richard Beckwith, country manager at Jurox, said: "The introduction of Alfaxan Multidose to our anaesthesia and analgesia portfolio ensures that Alfaxan is more versatile than ever.
"The Alfaxan range continues to provide greater certainty and control during anaesthetic procedures, contributing towards better patient stability and a stress-free experience for the team."
For more information, visit www.alfaxan.co.uk, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
The newsletter will include anaesthesia updates, bulletins and recaps, access to videos and downloadable resources.
Articles in Anaesthesia1ST are being written by Jurox’s technical advisors in collaboration with anaesthesia specialists such as Carl Bradbrook (European Veterinary Specialist in Anaesthesia and Analgesia and an RCVS Recognised Specialist in Veterinary Anaesthesia) and Ian Self (European Specialist in Veterinary Anaesthesia and Analgesia, Associate Professor in Veterinary Anaesthesia and Analgesia, Faculty of Medicine & Health Sciences, University of Nottingham).
The first newsletter launched on 15th May and included: ‘Capnography I – not just a load of hot air’, ‘Perspectives on premeds – Alpha-2 agonists’ and ‘What’s new in anaesthesia? Highlights of recent preoxygenation paper’.
Articles in future editions will include: ‘Capnography II – what happened to the elephants?’, ‘Pain, what a pain! Local and regional nerve blocks improve outcomes and welfare of patients’, “The Big Chill – temperature management in sedated and anaesthetised patients’ and ‘Perspectives on premeds – a complete series of articles covering the ins and outs of the different agents, how they compare and recommended use in the different patient types’.
Jurox says that downloadable resources will include a capnography cheat-sheet detailing different traces and their meaning, premedication drugs comparison tables and pre and post rabbit anaesthesia check-lists.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "We take great pride in our investment in educational initiatives to enable veterinary professionals to deliver best practice anaesthesia to their clients. The new Anaesthesia1ST newsletter further demonstrates our commitment to educational support resources to enable veterinary professionals to attain and maintain 1ST class anaesthesia for all patients."
To sign up to the Anaesthesia1ST newsletter, click here, visit the Alfaxan website – www.alfaxan.co.uk, contact your local Jurox technical sales representative or email Jurox at: info@jurox.co.uk.
The website now contains a range of information on Alfaxan including user experiences, sections on best practice anaesthesia, webinars and details of Jurox’s anaesthesia roadshows.
The webinars include a presentation which explains how to use Alfaxan to achieve the best anaesthetic experience for the patient. There is also series of short online webinars on rabbit anaesthesia:
An online CPD certificate will be issued to veterinary professionals who have viewed each webinar, after they have taken a short online questionnaire.
The Alfaxan website also offers downloadable resources such as the new Considerations for Anaesthetising Rabbits expert panel guidelines booklet, AVA Anaesthetic Safety Checklist Implemenation manual, AVA Anaesthetic Safety Checklist and Alfaxan resource guides, user guides, dose charts and monitoring charts.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "Our new Alfaxan website is an educational hub that enables veterinary professionals to learn more about best practice anaesthesia and how this can be implemented in their own clinics. With Alfaxan’s new pet rabbit indication we have included an emphasis on rabbit anaesthesia and how this differs from anaesthesia in cats and dogs."
For further information, visit www.alfaxan.co.uk, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
The booklet contains practical advice on handling rabbits, anaesthetic drugs, procedures and what to look out for from the moment the rabbit arrives into the practice up to recovery and homecare. Special attention is given to reducing anxiety in rabbit patients as much as possible at every stage.
Topics covered in the booklet include: medications in rabbits generally used according to the UK prescribing cascade, preparing for rabbit anaesthesia in clinic, staff training, an overview of anaesthetic drugs, the induction process and important points of difference, monitoring and recovery and adjunctive treatments.
Richard Beckwith, country manager of Jurox said: "Rabbits are prey species and often become stressed in the veterinary practice environment which can have a negative impact during anaesthesia and post-anaesthesia. Our new Considerations for Anaesthetising Rabbits expert panel guidelines booklet will help address this and raise anaesthesia and analgesia standards in veterinary practices."
For more information, visit www.alfaxan.co.uk, contact Jurox customer services on info@jurox.co.uk or telephone 0800 500 3871.
Rabbits are the third most commonly anaesthetised pet in the UK, however they have a seven times greater overall risk of perioperative death than dogs1.
Jurox says Alfaxan 10mg/ml solution for injection provides a wide safety margin, an excellent cardio-respiratory profile and is dosed to effect, making it an excellent choice for the anaesthetic induction of rabbits.
The company also says Alfaxan provides smooth and rapid induction and recovery, painless administration and good muscle relaxation with low impact on ventilation and blood pressure.
Richard Beckwith, country manager of Jurox (UK) Ltd said: "Rabbits are a growing pet population and increasingly play a more important part in UK vet practices, which is why Jurox has invested in research in this species.
"We are happy we can now support our vet and nurse clients by providing a new and reliable choice for induction of anaesthesia in pet rabbits that has been extensively trialed and researched.
"Alfaxan is a very versatile product as it is convenient for any type of situation, whether it is surgery on healthy animals or high risk patients such as pet rabbits. With Alfaxan we hope to make a contribution to the future of veterinary anaesthesia in the UK and are confident our clients will be able to deliver the best practice anaesthesia they believe in."
For more information, visit: Alfaxan.co.uk. Alternatively, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
Buprelieve is a 0.3mg/ml buprenorphine solution for injection, licensed for post-operative analgesia and to potentiate the sedative effects of other centrally-acting agents in dogs and horses. It can be administered by intramuscular or intravenous injection to dogs and cats and by intravenous injection to horses and is available in 10ml multi-dose glass vials.
Dr Rich Irvine BVSc MRCVS, veterinary services manager at Jurox (UK) Limited said: "We are delighted to be extending our range of products with the launch of Buprelieve which will provide veterinary practices with effective and economical analgesia.
"The launch of Buprelieve will be supported by our highly qualified team of veterinary surgeons who aim to deliver top quality help, advice and assistance for clinics wishing to perform best practice anaesthesia across all patient groups."
Jurox says it has been listening to the concerns of veterinary surgeons who say they want high quality generic medicines at affordable prices along with transparency as to what they are paying for each vial. As a result, the company says it is launching Buprelieve at a very affordable list price with a simple and generous introductory offer or rebate.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "Jurox prides itself on providing customers with a range of high quality medicines and we believe the launch of Buprelieve will also satisfy vets’ increasing requests for competitively priced products. We understand that providing high quality pain relief is critical and Buprelieve helps vets deliver the care they demand for their patients."
For more information, contact your local Jurox technical advisor, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.